CA3088401A1 - Dosing regimen for missed doses for long-acting injectable paliperidone esters - Google Patents

Dosing regimen for missed doses for long-acting injectable paliperidone esters Download PDF

Info

Publication number
CA3088401A1
CA3088401A1 CA3088401A CA3088401A CA3088401A1 CA 3088401 A1 CA3088401 A1 CA 3088401A1 CA 3088401 A CA3088401 A CA 3088401A CA 3088401 A CA3088401 A CA 3088401A CA 3088401 A1 CA3088401 A1 CA 3088401A1
Authority
CA
Canada
Prior art keywords
patient
reinitiation
dose
deltoid
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3088401A
Other languages
English (en)
French (fr)
Inventor
Srihari Gopal
Paulien Gerada Maria Ravenstijn
Alberto Russu
Mahesh Narain Samtani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3088401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CA3088401A1 publication Critical patent/CA3088401A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3088401A 2015-04-07 2016-04-01 Dosing regimen for missed doses for long-acting injectable paliperidone esters Abandoned CA3088401A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US62/144,054 2015-04-07
US201562162596P 2015-05-15 2015-05-15
US62/162,596 2015-05-15
CA2925908A CA2925908C (en) 2015-04-07 2016-04-01 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2925908A Division CA2925908C (en) 2015-04-07 2016-04-01 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
CA3088401A1 true CA3088401A1 (en) 2016-10-07

Family

ID=57072843

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2925908A Active CA2925908C (en) 2015-04-07 2016-04-01 Dosing regimen for missed doses for long-acting injectable paliperidone esters
CA3088401A Abandoned CA3088401A1 (en) 2015-04-07 2016-04-01 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2925908A Active CA2925908C (en) 2015-04-07 2016-04-01 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Country Status (27)

Country Link
US (1) US10143693B2 (enExample)
EP (3) EP3280416B1 (enExample)
JP (3) JP6728221B2 (enExample)
KR (3) KR102755145B1 (enExample)
AU (4) AU2016244801B2 (enExample)
BR (1) BR112017021383A2 (enExample)
CA (2) CA2925908C (enExample)
CY (1) CY1123203T1 (enExample)
DK (2) DK3280416T3 (enExample)
EA (1) EA037185B1 (enExample)
ES (2) ES2802299T3 (enExample)
FI (1) FI3744326T3 (enExample)
HR (2) HRP20240022T1 (enExample)
HU (2) HUE049485T2 (enExample)
IL (3) IL309340A (enExample)
LT (2) LT3280416T (enExample)
MA (1) MA41917B1 (enExample)
MD (2) MD3744326T2 (enExample)
NZ (1) NZ735952A (enExample)
PL (2) PL3280416T3 (enExample)
PT (2) PT3744326T (enExample)
RS (2) RS60510B1 (enExample)
SI (2) SI3280416T1 (enExample)
SM (2) SMT202000351T1 (enExample)
TW (1) TWI694825B (enExample)
UA (1) UA118732C2 (enExample)
WO (1) WO2016164218A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102755145B1 (ko) 2015-04-07 2025-01-14 잔센파마슈티카엔.브이. 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
EP3700531B1 (en) 2017-10-27 2025-06-25 Geneora Pharma (Shijiazhuang) Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
EP4356966A3 (en) 2020-11-30 2024-07-17 JANSSEN Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
FI4025189T3 (fi) * 2020-11-30 2024-07-02 Janssen Pharmaceutica Nv Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia
US11324751B1 (en) * 2020-11-30 2022-05-10 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
US11666697B2 (en) 2020-11-30 2023-06-06 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
CN118119394A (zh) 2021-08-20 2024-05-31 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
CA3230291A1 (en) * 2021-08-30 2023-03-09 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
KR102163196B1 (ko) * 2007-12-19 2020-10-12 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
EP2485712A1 (en) * 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
CA2742393A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
KR102755145B1 (ko) 2015-04-07 2025-01-14 잔센파마슈티카엔.브이. 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Also Published As

Publication number Publication date
RS60510B1 (sr) 2020-08-31
DK3744326T3 (da) 2024-02-05
KR102606678B1 (ko) 2023-11-24
SI3280416T1 (sl) 2020-07-31
EA201792209A1 (ru) 2018-02-28
CY1123203T1 (el) 2021-10-29
FI3744326T3 (fi) 2024-02-02
IL309340A (en) 2024-02-01
EP4349323A3 (en) 2024-06-12
KR102755145B1 (ko) 2025-01-14
LT3280416T (lt) 2020-06-25
SI3744326T1 (sl) 2024-02-29
PL3280416T3 (pl) 2020-12-14
TW201642863A (zh) 2016-12-16
JP7228503B2 (ja) 2023-02-24
PT3744326T (pt) 2024-01-15
EP4349323A2 (en) 2024-04-10
EP3280416B1 (en) 2020-04-22
EA037185B1 (ru) 2021-02-17
ES2967585T3 (es) 2024-05-03
DK3280416T3 (da) 2020-05-11
AU2016244801B2 (en) 2020-06-25
JP2021130680A (ja) 2021-09-09
AU2016244801A1 (en) 2017-10-05
MD3744326T2 (ro) 2024-05-31
EP3744326B1 (en) 2023-12-06
JP6728221B2 (ja) 2020-07-22
NZ735952A (en) 2022-02-25
JP7422277B2 (ja) 2024-01-26
SMT202300478T1 (it) 2024-01-10
IL254669A0 (en) 2017-11-30
WO2016164218A1 (en) 2016-10-13
UA118732C2 (uk) 2019-02-25
TWI694825B (zh) 2020-06-01
NZ758246A (en) 2024-05-31
RS65024B1 (sr) 2024-01-31
IL254669B1 (en) 2024-01-01
AU2022221405A1 (en) 2022-09-15
CA2925908A1 (en) 2016-10-07
ES2802299T3 (es) 2021-01-18
HK1249047A1 (en) 2018-10-26
AU2024227790A1 (en) 2024-11-21
BR112017021383A2 (pt) 2018-07-03
CA2925908C (en) 2020-09-01
EP3744326A1 (en) 2020-12-02
HUE049485T2 (hu) 2020-09-28
IL254669B2 (en) 2024-05-01
JP2020090498A (ja) 2020-06-11
SMT202000351T1 (it) 2020-09-10
LT3744326T (lt) 2023-12-27
HRP20201027T1 (hr) 2020-12-11
EP3280416A4 (en) 2019-01-23
HUE065435T2 (hu) 2024-05-28
JP2018510894A (ja) 2018-04-19
HRP20240022T1 (hr) 2024-03-29
AU2020239611A1 (en) 2020-10-15
AU2020239611B2 (en) 2022-07-21
AU2022221405B2 (en) 2024-08-01
PL3744326T3 (pl) 2024-03-25
KR20250013293A (ko) 2025-01-31
MA41917B1 (fr) 2020-07-29
MD3280416T2 (ro) 2020-10-31
US20170281629A1 (en) 2017-10-05
EP3280416A1 (en) 2018-02-14
PT3280416T (pt) 2020-06-30
US10143693B2 (en) 2018-12-04
KR20170134583A (ko) 2017-12-06
IL324059A (en) 2025-12-01
KR20230162162A (ko) 2023-11-28

Similar Documents

Publication Publication Date Title
AU2022221405B2 (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
JP7792409B2 (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
CN116528836A (zh) 与延长释放帕潘立酮可注射制剂相关的给药方案
KR20240049580A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
HK40110149A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
JP7792959B2 (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
HK1249047B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40111349A (en) Dosing regimens associated with extended release paliperidone injectable formulations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200729

EEER Examination request

Effective date: 20200729

FZDE Discontinued

Effective date: 20230208

FZDE Discontinued

Effective date: 20230208